Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more
Anixa Biosciences Inc (ANIX) - Total Liabilities
Latest total liabilities as of January 2026: $1.39 Million USD
Based on the latest financial reports, Anixa Biosciences Inc (ANIX) has total liabilities worth $1.39 Million USD as of January 2026.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Anixa Biosciences Inc - Total Liabilities Trend (1985–2025)
This chart illustrates how Anixa Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Anixa Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Anixa Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BRIM Biotechnology Inc.
TWO:6885
|
Taiwan | NT$25.06 Million |
|
Prairie Operating Co. Common Stock
OTCQB:PROP
|
USA | $764.37 Million |
|
Accsys Technologies PLC
PINK:ACSYF
|
USA | $104.69 Million |
|
Bansal Wire Industries Ltd
NSE:BANSALWIRE
|
India | ₹9.33 Billion |
|
OBOOK Holdings Inc. Class A Common Shares
NASDAQ:OWLS
|
USA | $30.60 Million |
|
Sonaecom SGPS
LS:SNC
|
Portugal | €41.77 Million |
Liability Composition Analysis (1985–2025)
This chart breaks down Anixa Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anixa Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anixa Biosciences Inc (1985–2025)
The table below shows the annual total liabilities of Anixa Biosciences Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | $2.13 Million | -21.20% |
| 2024-10-31 | $2.70 Million | +25.66% |
| 2023-10-31 | $2.15 Million | -2.76% |
| 2022-10-31 | $2.21 Million | +48.40% |
| 2021-10-31 | $1.49 Million | +25.41% |
| 2020-10-31 | $1.19 Million | -19.76% |
| 2019-10-31 | $1.48 Million | +17.09% |
| 2018-10-31 | $1.27 Million | +42.23% |
| 2017-10-31 | $889.49K | -80.83% |
| 2016-10-31 | $4.64 Million | +8.38% |
| 2015-10-31 | $4.28 Million | -15.14% |
| 2014-10-31 | $5.05 Million | -42.40% |
| 2013-10-31 | $8.76 Million | +27.80% |
| 2012-10-31 | $6.85 Million | -9.66% |
| 2011-10-31 | $7.59 Million | +39.22% |
| 2010-10-31 | $5.45 Million | +1.00% |
| 2009-10-31 | $5.40 Million | -6.44% |
| 2008-10-31 | $5.77 Million | +749.66% |
| 2007-10-31 | $678.81K | +16.68% |
| 2006-10-31 | $581.79K | +67.07% |
| 2005-10-31 | $348.23K | -21.41% |
| 2004-10-31 | $443.12K | +29.46% |
| 2003-10-31 | $342.29K | -17.33% |
| 2002-10-31 | $414.02K | -82.72% |
| 2001-10-31 | $2.40 Million | +79.21% |
| 2000-10-31 | $1.34 Million | -25.73% |
| 1999-10-31 | $1.80 Million | +28.57% |
| 1998-10-31 | $1.40 Million | +16.67% |
| 1997-10-31 | $1.20 Million | -36.84% |
| 1996-10-31 | $1.90 Million | +533.33% |
| 1995-10-31 | $300.00K | +50.00% |
| 1994-10-31 | $200.00K | -60.00% |
| 1993-10-31 | $500.00K | +66.67% |
| 1992-10-31 | $300.00K | +200.00% |
| 1991-10-31 | $100.00K | 0.00% |
| 1990-10-31 | $100.00K | 0.00% |
| 1989-10-31 | $100.00K | 0.00% |
| 1988-10-31 | $100.00K | 0.00% |
| 1987-10-31 | $100.00K | -50.00% |
| 1986-10-31 | $200.00K | 0.00% |
| 1985-10-31 | $200.00K | -- |